Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Kevin J Harrington"'
Autor:
Clifton D. Fuller, Baukelien van Triest, Bruce D. Minsky, Rob H N Tijssen, Joel W. Goldwein, Stella Mook, Kevin J. Harrington, John P. Christodouleas, Uulke A. van der Heide, Robert Huddart, Ananya Choudhury, Kristina Orrling, Sophie R de Mol van Otterloo, Robbert J.H.A. Tersteeg, Susan Lalondrelle, Dave Eggert, Anna M. Kirby, Chia-Lin Tseng, Beth Erickson, Uwe Oelfke, Hafid Akhiat, Marlies E. Nowee, K.J. Brown, Claire McCann, Corinne Faivre-Finn, Erwin L. A. Blezer, Emma Hall, Lois A. Daamen, Helena M. Verkooijen, Martijn Intven, Christopher J. Schultz, Alison Tree, Shaista Hafeez, Marielle E.P. Philippens, Arjun Sahgal, William A. Hall
Publikováno v:
Int J Radiat Oncol Biol Phys
International Journal of Radiation Oncology-Biology-Physics, 111(4), 867-875. ELSEVIER SCIENCE INC
International Journal of Radiation Oncology-Biology-Physics, 111(4), 867-875. ELSEVIER SCIENCE INC
Purpose: High-field magnetic resonance-linear accelerators (MR-Linacs), linear accelerators combined with a diagnostic magnetic resonance imaging (MRI) scanner and online adaptive workflow, potentially give rise to novel online anatomic and response
Autor:
Jérôme Fayette, Vijayvel Jayaprakash, Kevin J. Harrington, Robert L. Ferris, Li Li, Maura L. Gillison, Peter Brossart, Nabil F. Saba, Joël Guigay, Lisa Licitra, Naomi Kiyota, George R. Blumenschein
Publikováno v:
Oral oncology
Objectives: Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. Nivolumab is the only immunotherapy to
Autor:
Lisa Pickering, Nalinie Joharatnam-Hogan, Fiona Kinnaird, Andrew Furness, Mary Wu, Daqi Deng, Sina Namjou, Sarah Sarker, Aljosja Rogiers, Aida Murra, Justine Korteweg, Nicholas van As, Nicholas C. Turner, Anna Robinson, Joanne Droney, Kema Peat, Shaman Jhanji, Mike Gavrielides, Isla Leslie, Lauren Dowdie, Tara Foley, Christina Messiou, Natalie Ash, Taja Barber, Andrea Emslie-Henry, Simon Caidan, Karolina Rzeniewicz, Katalin A. Wilkinson, Ruth Harvey, Annika Fendler, Kate Tatham, Andreas M. Schmitt, Sunil Iyengar, Shreerang Bhide, Kayleigh Kelly, David L.V. Bauer, Benjamin Shum, Kim Edmonds, Gail Gardner, Scott Shepherd, Mark Ethell, Laura Amanda Boos, Liam Welsh, Robert J. Wilkinson, Lucy Holt, Alicia Okines, William Gordon, James I. MacRae, Maddalena Cerrone, Kevin J. Harrington, Mary Mangwende, Hamid Ahmod, Olivia Curtis, Emma Nicholson, Darren Murray, Susana Banerjee, Firza Gronthoud, Bhavna Oza, Naureen Starling, Wenyi Xie, Alison Reid, Karla Lingard, Ana Agua-Doce, Charles Swanton, Sacheen Kumar, Lewis Au, Michael Howell, James Larkin, Camille L. Gerard, Emma C Wall, Jessica Bazin, Ian Chau, Robin L. Jones, Fiona Byrne, Robyn L. Shea, Denise Kelly, Nadia Yousaf, Steve Gamblin, Kate Young, Sonia Gandhi, Susanna Walker, Eleanor Carlyle, Javier Pascual, David Cunningham, Samra Turajlic, Clemency Stephenson, Zayd Tippu, Gavin Kelly, Mary O'Brien, Sheima Farag, Molly O’Flaherty, George Kassiotis, Wanyuan Cui, Justin Mencel, Lyra Del Rosario, Simon Rodney
Publikováno v:
Nature cancer
Nature Cancer
Nature Cancer
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f90b7e7f14703f40105aa2f1e5740b1a
https://doi.org/10.21203/rs.3.rs-916303/v1
https://doi.org/10.21203/rs.3.rs-916303/v1
Autor:
Sara Reis, Intan Hamid, Sophie McGrath, Susannah Stanway, Alicia Okines, Jaishree Bhosle, Vasileios Angelis, Marco Gerlinger, Heba Soliman, Zayd Tippu, Firza Gronthoud, Robin L. Jones, Emma Cottier, Charlotte Fribbens, Jillian Noble, David Watkins, Spyridon Gennatas, Kroopa Joshi, Pablo Nenclares, Kevin J. Harrington
Publikováno v:
European Journal of Cancer
Background In light of the coronavirus disease 2019 (COVID-19) pandemic, cancer centres in the United Kingdom and Europe re-organised their services at an unprecedented pace, and many patients with cancer have had their treatments severely disrupted.
Autor:
Christopher M. Nutting, Dorothy M. Gujral, Michelle Long, Kevin J. Harrington, Justin W. G. Roe
Publikováno v:
Clinical Oncology. 29:42-50
AIMS Recently, carotid-sparing intensity-modulated radiotherapy (IMRT) for early laryngeal glottis (T1/T2N0M0) cancer has generated interest in the hope of avoiding long-term carotid toxicity, as well as concerns relating to geographical misses and l
Autor:
Catherine Lemon, Dorothy M. Gujral, Paul Sanghera, James P Morden, Emma Hall, M. Emson, Simon Gollins, Q van den Blink, Matthew Beasley, L. Fresco, Mererid Evans, L Luxon, S.A. Bhide, E. Wells, Katie L. Newbold, Costar Investigators, Christopher M. Nutting, E. De Winton, M. Sivaramalingam, Kevin J. Harrington, Audrey Cook, Stephanie Witts, M Joseph, N. N Srihari, M. Sydenham, R Mendes, Martin Robinson, J Simpson, Robin Prestwich, A Miah
Publikováno v:
European Journal of Cancer
Purpose About 40–60% of patients treated with post-operative radiotherapy for parotid cancer experience ipsilateral sensorineural hearing loss. Intensity-modulated radiotherapy (IMRT) can reduce radiation dose to the cochlea. COSTAR, a phase III tr
Autor:
Cyril Fisher, Arndt Hartmann, Christopher A. French, Khin Thway, Carmo Martins, Isabel Fonseca, Ryan Barrette, Abbas Agaimy, Kevin J. Harrington
Publikováno v:
The American journal of surgical pathology. 42(7)
NUT carcinoma (NC) represents a rare subset of highly aggressive poorly differentiated carcinomas characterized by rearrangement of the NUT (aka NUTM1, nuclear protein in testis) gene, most commonly fused to BRD4. Originally described as a mediastina
Autor:
Navita Somaiah, Joan N. Kyula, James T. Paget, Paul Harris, Aadil A. Khan, Richard G. Vile, T. Pencavel, Jessica K.R. Boult, Martin Halle, David Mansfield, Hardev Pandha, R. Seth, Martin McLaughlin, Kevin J. Harrington, Simon P. Robinson, Alan Melcher, Michelle J. Wilkinson, Victoria Roulstone
Publikováno v:
Science Translational Medicine. 10
Improvements in cancer survival mean that long-term toxicities are being increasingly recognised that contribute to the morbidity of cancer survivorship. Late adverse effects (LAEs) in normal tissues after radiotherapy (RT) are characterized by vascu
Autor:
N. Würdemann, Terence M. Jones, Max Robinson, Anders Näsman, Nikolaos Batis, David Hebbelstrup Jensen, Stefan Gattenlöhner, Hisham Mehanna, Eva Munck-Wikland, Christian Dehlendorff, Shachi Jenny Sharma, Katalin Kiss, Christian Grønhøj, Tina Dalianis, Kevin J. Harrington, Elo Andersen, Linda Marklund, Christian von Buchwald, Jeppe Friborg, Steffen Wagner, Jens Peter Klussmann, Claus Wittekindt, Stuart Winter, Torbjörn Ramqvist, Rachel Spruce
Publikováno v:
British Journal of Cancer
Grønhøj, C, Jensen, D H, Dehlendorff, C, Marklund, L, Wagner, S, Mehanna, H, Munck-Wikland, E, Ramqvist, T, Näsman, A, Wittekindt, C, Würdemann, N, Sharma, S J, Gattenlöhner, S, Kiss, K, Andersen, E, Spruce, R, Batis, N, Robinson, M, Harrington, K, Winter, S, Jones, T M, Klussmann, J P, Dalianis, T, Friborg, J & von Buchwald, C 2018, ' Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status : a European Multicentre Study (OroGrams) ', British Journal of Cancer, vol. 118, no. 12, pp. 1672-1681 . https://doi.org/10.1038/s41416-018-0107-9
BRITISH JOURNAL OF CANCER
Grønhøj, C, Jensen, D H, Dehlendorff, C, Marklund, L, Wagner, S, Mehanna, H, Munck-Wikland, E, Ramqvist, T, Näsman, A, Wittekindt, C, Würdemann, N, Sharma, S J, Gattenlöhner, S, Kiss, K, Andersen, E, Spruce, R, Batis, N, Robinson, M, Harrington, K, Winter, S, Jones, T M, Klussmann, J P, Dalianis, T, Friborg, J & von Buchwald, C 2018, ' Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status : a European Multicentre Study (OroGrams) ', British Journal of Cancer, vol. 118, no. 12, pp. 1672-1681 . https://doi.org/10.1038/s41416-018-0107-9
BRITISH JOURNAL OF CANCER
BACKGROUND: The proxy marker for human papillomavirus (HPV), p16, is included in the new AJCC 8th/UICC 8th staging system, but due to incongruence between p16 status and HPV infection, single biomarker evaluation could lead to misallocation of patien
Autor:
Hui Jia, Anthony T.C. Chan, David Price, Kevin J. Harrington, Lip Wai Lee, Graham S. Taylor, James E. Turner, Alan B. Rickinson, Lesley McGuigan, Edwin P. Hui, Jen Matthews, Neil Steven, Kristin Ladell, Andrew Hartley, Manjit Tanday, Ceri Edwards, Steve Wilson, Claudia Roberts
Publikováno v:
Taylor, G S, Jia, H, Harrington, K, Lee, L W, Turner, J E, Ladell, K, Price, D A, Tanday, M, Matthews, J, Roberts, C, Edwards, C, McGuigan, L, Hartley, A, Wilson, S, Hui, E P, Chan, A T C, Rickinson, A B & Steven, N M 2014, ' A recombinant modified vaccinia Ankara vaccine encoding Epstein-Barr virus (EBV) target antigens : a phase I trial in UK patients with EBV-positive cancer ', Clinical Cancer Research, vol. 20, no. 19, pp. 5009-5022 . https://doi.org/10.1158/1078-0432.CCR-14-1122-T
Purpose: Epstein–Barr virus (EBV) is associated with several cancers in which the tumor cells express EBV antigens EBNA1 and LMP2. A therapeutic vaccine comprising a recombinant vaccinia virus, MVA-EL, was designed to boost immunity to these tumor